Research Articles >
College of Science >
Please use this identifier to cite or link to this item:
|Title: ||Enhanced oral bioavailability and anti-gout activity of -shogaol-loaded solid lipid nanoparticles|
|Authors: ||Wang, Qilong|
Firempong, Caleb K.
|Issue Date: ||Aug-2018|
|Publisher: ||Elsevier B.V.|
|Abstract: ||-Shogaol, an alkylphenol compound purified from the root and stem of ginger (Zingiber officinale), has attracted
considerable interest due to its potential anticancer, antioxidative and antirheumatic properties.
However, the oral bioavailability of -shogaol has been severely limited because of its poor solubility. In this
study, a significant quantity of high-purity -shogaol (yield: 3.6%; purity: 98.65%) was extracted and encapsulated
in solid lipid nanoparticles (SLNs) via high-pressure homogenization (encapsulation efficiency:
87.67%) to improve its solubility and oral bioavailability. The resulting -shogaol-loaded solid lipid nanoparticles
(SSLNs) were stable, homogeneous and well-dispersed. Its mean particle size and zeta potential were
73.56 ± 5.62 nm and −15.2 ± 1.3 mV, respectively. Importantly, the in vitro release profile and in vivo oral
bioavailability of SSLNs were significantly improved compared with the free drug. Furthermore, the SSLNs could
remarkably lower the uric acid level via inhibiting the activity of xanthine oxidase and reduce the production of
interleukin-1β (IL-1β) and tumor necrosis factor (TNF-α) in the hyperuricemia/gouty arthritis rat model, when
compared to the free -shogaol. Collectively, SLNs could serve as a promising drug delivery system to improve
the oral bioavailability of -shogaol for effective treatment of gouty arthritis.|
|Description: ||An article published by Elsevier B.V. and also available at https://doi.org/10.1016/j.ijpharm.2018.08.028|
|Appears in Collections:||College of Science|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.